The effect of leucine and nandrolone decanoate supplementation on muscle loss during immobilisation

The effect of leucine and nandrolone decanoate supplementation on muscle loss during immobilisation - nandrolone and leucine during immobilisation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON41995

Enrollment

Registered

2015-04-13

Start date

2015-09-07

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disuse atrophy muscle loss

Interventions

One leg will be immobilized at a 30 degree knee joint angle of flexion for 7 days by means of a full leg cast. In addition, participants will ad random be allocated to the leucine group or nandrolon

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male Aged from 18-35 years 18.5

Exclusion criteria

Exclusion criteria: (Family) history of thromboembolic events Smoking Recent surgery

Design outcomes

Primary

Measure	Time frame
Quadriceps CSA	—

Secondary

Measure	Time frame
whole upper leg muscle CSA muscle fiber type specific CSA muscle fiber type-specific satellite cell content 1RM muscle strength	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)